MAPT and Parkinson disease: Furthermore, new targets are represented by imidazoline 2 for astrogliosis using 11C-BU99008 PET, with preliminary findings indicating increased uptake in the frontal, temporal, parietal, and occipital cortices in PD [165], and monoamine oxidase B expressed in reactive astrocytes using 18F-THK5351, also binding to tau and displaying longitudinal increase in patients with CBS [166], and the more selective 11C-SMBT1 PET tracer [167].